User login
Click here to read the supplement.
This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.
In this CME supplement, you will learn to:
- Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
- Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
- Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
- Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection
Click here to read the supplement.
After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP
Click here to read the supplement.
This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.
In this CME supplement, you will learn to:
- Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
- Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
- Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
- Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection
Click here to read the supplement.
After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP
Click here to read the supplement.
This activity is supported by an educational grant from Astellas and Medivation, Inc. a Pfizer company, Janssen Biotech, Inc., administered byJanssen Scientific Affairs, LLC. and Sanofi Genzyme.
In this CME supplement, you will learn to:
- Identify best practices for integrating currently available treatment options for advanced prostate cancer, including immunologic therapies, new secondary hormonal agents, chemotherapy, and radiopharmaceuticals
- Describe new management options for metastatic hormonesensitive prostate cancer (mHSPC)
- Outline considerations for current and emerging therapies in the management of patients with metastatic castration-resistant prostate cancer (mCSPC)
- Understand how the molecular and biochemical underpinnings of mCRPC can impact treatment course and selection
Click here to read the supplement.
After reading, take the posttest evaluation at https://www.surveymonkey.com/r/WMMYNHP
